In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beximco Expands In US With Eight ANDAs From Sandoz

Executive Summary

Beximco has bolstered its position in the US by bumping up its portfolio to 14 approved generics through a deal with Sandoz for a portfolio of eight ANDAs.

You may also be interested in...



Beximco And Mylan Strike Biosimilars Deal

Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.

Beximco Sees Profit Jump By A Sixth

Bangladesh’s biggest pharmaceutical company, Beximco Pharmaceuticals, has posted a 16.7% jump in after-tax profit in its financial first half, powered by double-digit domestic and export revenue growth.

Bangladesh’s Beximco Sees Exports Boom As It Expands in North America

Shipping a fourth product to the US, as well as two launches in Canada, ensured exports accounted for more than a tenth of Bangladeshi producer Beximco’s half-year turnover.

Related Content

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel